Barbara Angehrn Pavik, Asceneuron CEO
July 16, 2024 03:00 AM EDT
Financing
Startups

Alzheimer's biotech As­ceneu­ron rais­es $100M to see if it can com­pete with Lil­ly, Bio­gen on tau

Kyle LaHucik

Senior Reporter

A small Swiss biotech has raised a $100 mil­lion Se­ries C to start test­ing its oral small mol­e­cule for Alzheimer’s dis­ease in a Phase 2 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Se­cre­tive Tree­line Bio­sciences dis­clos­es $421M fi­nanc­ing in fil­ing

FDA ap­proves Ab­b­Vie's 24-hour Parkin­son's in­fu­sion ther­a­py af­ter two CRLs

House’s promi­nent Chi­na crit­ic Jim Mc­Gov­ern leads op­po­si­tion to Biose­cure Act: ‘I would pre­fer to go back to the ...

Benev­o­len­tAI CEO is out af­ter less than a year on the job

Sage shakes up se­nior man­age­ment, slash­es pipeline, sheds 33% of staff

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times